The IN VIVO Blog (blog) |
Deals Of The Week: Isis Rethinks Its Partnering Strategy
The IN VIVO Blog (blog) … arthritis drug Humira (adalimumab). The collaboration will involve biosimilar versions of four oncology drugs, including Roche/Genentech Inc.’s Rituxan (rituximab), Bristol-Myers Squibb Co./Eli Lilly & Co.’s Erbitux (cetuximab), Roche/Genentech’s … |
Medscape |
Physician Gave Chemo to Patients Without Cancer, Feds Say
Medscape For example, Dr. Fata would order 56 doses of rituximab (Rituxan, Genentech) over the course of 2 years for a patient with non-Hodgkin’s lymphoma compared with 12 doses that a “normal oncologist” might order. Dr. Fata Owned Firm That Did PET Scans, … Oakland County cancer doctor accused of unnecessary treatments, defrauding …Detroit Free Press |
Off-label biologic use raises cost and safety concernsRheumatology UpdateThe study of Australian public hospitals over a six-month period found the monoclonal antibody rituximab was prescribed 364 times for 63 conditions that were not approved under th…
|
Study shows who survives Burkitt lymphoma
Medical Xpress The same regimen of intensive chemotherapy and the monoclonal antibody rituximab are recommended for most patients. “There was little available for Burkitt lymphoma in terms of prognostic factors, indicators or scoring,” said Dr. Jorge Castillo, an … |
Infinity Reports Second Quarter 2013 Financial Results and Provides Company …DailyFinance… announced the initiation of a Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg BID in approximate…
Infinity Pharmaceuticals Inc. (INFI): Infinity Pharmaceuticals Management …Seeking AlphaThis open label single-arm study is designed to evaluate the safety and efficacy of IPI-145 administered 25 mg BID in approximately 120 patients with Indolent Lym…
Infinity Reports Second Quarter 2013 Financial Results and Provides Company …Wall Street Journal… of a Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg BID in approximately 120 patients wi…
|
Kite Pharma Appoints Leading Cancer Immunotherapy Experts to its Scientific …
PR Newswire (press release) He was the first to successfully treat human lymphoma with a monoclonal antibody, and made important contributions to the development of rituximab (Rituxan®) for the treatment of lymphoma. Dr. Levy has received international acclaim for his work … |
|
Study shows who survives Burkitt lymphoma
EurekAlert (press release) The same regimen of intensive chemotherapy and the monoclonal antibody rituximab are recommended for most patients. “There was little available for Burkitt lymphoma in terms of prognostic factors, indicators or scoring,” said Dr. Jorge Castillo, an … |
Insider Monkey (blog)Sanofi SA (ADR) (SNY), GlaxoSmithKline plc (ADR) (GSK): This Company Is …Insider Monkey (blog)In protein based therapy, Lemtrada competes with late stage therapeutic candidates such as Daclizumab, Rituximab, and Ofatumumab. Dacli…